Insights
In-depth articles and expert analysis from pharmaceutical leaders, exploring advances in life sciences, drug development and the trends shaping healthcare innovation.
FDA Expedited IND Pilot Targets Faster First-In-Human Trials
CDRH Rare Disease Impact Initiative Sets New FDA Focus
Explore All Insights
Browse our complete library of expert articles and analysis. Explore content across science, policy and life sciences innovation.
Co-ordinated EU GMP Inspection Guidelines: What You Need to Know
New EU GMP inspection guidelines take effect in September 2026. Here is what you need to know about joint inspections, planning, and reporting.
World’s First Live AI-Assisted Brain Surgery
In the world’s first, London surgeons have used real-time AI to protect a patient's sight during live brain surgery. See what the trial’s AI framework means for MedTech.
AI in Healthcare: OpenAI and Epic Integration Connects EHRs
OpenAI and Epic integration brings AI healthcare into EHR workflows, connecting patient records with ChatGPT for Healthcare to advance research and patient care.
The Strategic Role of CDMOs in Pharma Manufacturing
CDMOs in pharmaceutical manufacturing are becoming strategic partners, providing technical expertise, capacity, technology, and quality oversight.
Endpoints in Gynaecological Oncology Clinical Trials
Gynaecological oncology clinical trials reveal that survival gains and trial design do not always align. Here is what clinical development teams should learn.
FDA Clinical Trial Oversight Tightens Globally
FDA clinical trial oversight is intensifying globally as the agency raises expectations for GCP, foreign site inspections, data integrity, and patient protection.
Digital Health Technologies in Clinical Drug Development
Digital health technologies in clinical drug development need more than data. Explore validation, standards, digital endpoints, patient value, and regulation.
Why Does the True Impact of AI in Drug Discovery Lag?
AI in drug discovery keeps making headlines, but clinical success rates barely move. A new Nature Reviews Perspective explains why, and what pharma should do next.
Synthetic Genetic Codes Move Closer to Programmable Biology
Synthetic genetic codes are moving closer to programmable biology as automated cell-free systems enable faster testing of new protein chemistries in R&D.
Bioprocessing Is Becoming a Smarter Manufacturing System
Bioprocessing is becoming more connected, automated, and data-driven. Here is what smarter process control means for biopharma manufacturing.
What Sponsors Need to Know About UK Combined Review 2026
UK Combined Review unifies MHRA and ethics review for CTIMPs, reshaping approval timelines, submissions, and sponsor planning under UK trial reform.
RCT Recruitment Prediction: Better Statistics, Better Trials
RCT recruitment prediction can improve trial planning by using Poisson and Bayesian models to estimate enrolment rates, uncertainty, and recruitment risk.